Roche Advances Obesity Pipeline with Promising Enicepatide and Petrelintide Data Ahead of ADA 2026

Roche is continuing to strengthen its position in the rapidly growing obesity treatment market. The company recently announced that new clinical data from its obesity portfolio will be presented at the 2026 American Diabetes Association (ADA) Scientific Sessions.
The upcoming presentations will focus on two investigational medicines, enicepatide and petrelintide, which are being developed to help people living with obesity, overweight, and related conditions such as type 2 diabetes.
The data add to Roche’s growing efforts to address some of the biggest challenges in obesity treatment, including long-term weight management, treatment adherence, safety, and tolerability.
Roche Expands Its Focus on Obesity Care
Obesity is becoming one of the most significant healthcare challenges worldwide. It is linked to more than 200 health conditions, including type 2 diabetes, cardiovascular disease, fatty liver disease, and chronic kidney disease.
Current estimates suggest that by 2035, more than four billion people worldwide could be living with overweight or obesity. This growing health burden is creating increasing demand for effective and sustainable treatment options.
Roche believes its obesity pipeline can offer patients more personalized treatment approaches that fit different needs and treatment goals.
According to Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, the latest clinical findings demonstrate the strength of the company's obesity portfolio and the potential for more individualized treatment strategies.
Enicepatide Shows Potential as a Next-Generation Weight Loss Therapy
One of the key programs being highlighted at ADA 2026 is enicepatide, previously known as CT-388.
Enicepatide is an investigational once-weekly injectable medicine that targets both the GLP-1 and GIP receptors. These receptors play important roles in appetite regulation, metabolism, and blood sugar control.
The upcoming late-breaking presentation will feature results from the Phase II CT388-103 study, which evaluated weight loss outcomes in people living with overweight or obesity.
At the same time, Roche is also running another Phase II study known as CT388-104. This trial is examining the medicine's efficacy, safety, and tolerability in people who are overweight or obese and also have type 2 diabetes.
The company believes enicepatide has the potential to become an important standalone treatment while also serving as a foundation for future combination therapies within Roche’s cardiometabolic pipeline.
How Enicepatide Works
Enicepatide was specifically designed to provide strong activity at both GLP-1 and GIP receptors while minimizing beta-arrestin recruitment.
This may sound highly technical, but the goal is simple.
By reducing receptor internalization and desensitization, Roche hopes the medicine can maintain its effectiveness for longer periods. In theory, this could help patients achieve sustained treatment benefits while potentially improving tolerability.
The once-weekly dosing schedule may also support long-term treatment adherence, which remains one of the biggest challenges in obesity management.
Petrelintide Delivers Encouraging Phase II Results
The second major obesity asset attracting attention is petrelintide.
Roche plans to present late-breaking results from the Phase II ZUPREME-1 trial, which evaluated the efficacy and safety of petrelintide in people living with overweight and obesity.
Petrelintide belongs to a different class of obesity medicines known as amylin analogs.
Unlike GLP-1-based treatments, amylin-based therapies work through a separate biological pathway that helps regulate appetite and food intake.
The data from ZUPREME-1 are expected to provide additional insight into how petrelintide may contribute to long-term weight management.
Understanding the Role of Amylin in Weight Management
Amylin is a naturally occurring hormone produced by the pancreas and released alongside insulin after eating.
One of its key functions is helping people feel full sooner and stay satisfied for longer periods.
Petrelintide is a long-acting amylin analog designed for once-weekly administration. By activating amylin receptors, the medicine aims to enhance satiety signals and support meaningful weight reduction.
The drug was also designed to maintain chemical and physical stability, allowing potential co-formulation or co-administration with other peptide-based therapies.
This flexibility could make petrelintide an attractive component of future combination treatment approaches.
Ongoing Development of Petrelintide
Roche is not limiting petrelintide development to obesity alone.
The ongoing Phase II ZUPREME-2 study is evaluating petrelintide against placebo in people living with overweight or obesity who also have type 2 diabetes.
The company sees significant potential for petrelintide both as a standalone therapy and in combination with enicepatide.
This dual approach could provide physicians with additional tools to tailor treatment based on individual patient needs.
Roche Moves Both Programs into Phase III Development
One of the most important announcements accompanying the ADA presentations is Roche’s decision to move both enicepatide and petrelintide into Phase III development.
Advancing two obesity candidates simultaneously demonstrates the company's confidence in the data generated so far.
In addition, Roche plans to launch a Phase II multi-arm combination study during mid-2026. This study will explore how different obesity therapies within the company’s pipeline may work together.
Combination therapies are becoming an increasingly important area of focus in obesity medicine as researchers look for ways to improve efficacy while maintaining acceptable safety and tolerability profiles.
Why Long-Term Treatment Matters
One of the biggest challenges in obesity care is maintaining weight loss over time.
Many patients struggle with long-term adherence due to side effects, treatment fatigue, or reduced effectiveness.
Roche’s obesity strategy focuses not only on achieving meaningful weight reduction but also on creating treatment options that patients can stay on comfortably for extended periods.
The distinct safety and tolerability profiles observed with enicepatide and petrelintide could help address this unmet need.
While additional data are still needed, the company believes these therapies may eventually support more sustainable long-term weight management.
The Growing Competition in Obesity Treatment
The obesity treatment market has become one of the most competitive areas in the pharmaceutical industry.
With rising global obesity rates and growing demand for effective therapies, major pharmaceutical companies are investing heavily in next-generation weight management medicines.
Roche’s expanding pipeline reflects its ambition to become a significant player in this rapidly evolving field.
The combination of GLP-1/GIP technology through enicepatide and amylin-based therapy through petrelintide gives the company multiple approaches to address obesity and its related health complications.
Looking Ahead
The upcoming ADA 2026 presentations will provide a closer look at how Roche’s obesity medicines are performing in clinical development.
The latest findings from enicepatide and petrelintide suggest that Roche is building a diversified obesity portfolio capable of addressing different patient needs and treatment goals.
With both programs advancing into Phase III studies and combination trials on the horizon, Roche is positioning itself for a larger role in the future of obesity treatment.
As obesity continues to affect millions of people worldwide, new treatment options that offer strong efficacy, improved tolerability, and long-term sustainability could play a critical role in improving patient outcomes and reducing the burden of chronic disease.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!